MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- SUN PHARMA - MYLAN (US)
SUN PHARMA vs MYLAN (US) - Comparison Results
SUN PHARMA Change
Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More
MYLAN (US)
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
Financials
 SUN PHARMA  MYLAN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| SUN PHARMA Mar-19 |
MYLAN Dec-18 |
SUN PHARMA/ MYLAN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 679 | 3,393 | - | |
| Low | Rs | 375 | 1,868 | - | |
| Sales per share (Unadj.) | Rs | 121.1 | 1,561.2 | - | |
| Earnings per share (Unadj.) | Rs | 13.4 | 42.4 | - | |
| Cash flow per share (Unadj.) | Rs | 20.7 | 334.7 | - | |
| Dividends per share (Unadj.) | Rs | 2.75 | 0 | - | |
| Dividend yield (eoy) | % | 0.5 | 0 | - | |
| Book value per share (Unadj.) | Rs | 172.6 | 1,689.0 | - | |
| Shares outstanding (eoy) | m | 2,399.26 | 514.50 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 4.4 | 1.7 | 258.3% | |
| Avg P/E ratio | x | 39.4 | 62.0 | 63.5% | |
| P/CF ratio (eoy) | x | 25.5 | 7.9 | 324.3% | |
| Price / Book Value ratio | x | 3.1 | 1.6 | 196.1% | |
| Dividend payout | % | 20.6 | 0 | - | |
| Avg Mkt Cap | Rs m | 1,264,650 | 1,353,254 | 93.5% | |
| No. of employees | `000 | 17.5 | 35.0 | 50.0% | |
| Total wages/salary | Rs m | 59,671 | 0 | - | |
| Avg. sales/employee | Rs Th | 16,608.1 | 22,950.1 | 72.4% | |
| Avg. wages/employee | Rs Th | 3,409.6 | 0 | - | |
| Avg. net profit/employee | Rs Th | 1,833.8 | 623.2 | 294.3% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 290,659 | 803,254 | 36.2% | |
| Other income | Rs m | 10,255 | 0 | - | |
| Total revenues | Rs m | 300,914 | 803,254 | 37.5% | |
| Gross profit | Rs m | 63,076 | 207,852 | 30.3% | |
| Depreciation | Rs m | 17,533 | 150,401 | 11.7% | |
| Interest | Rs m | 5,553 | 38,634 | 14.4% | |
| Profit before tax | Rs m | 50,246 | 18,818 | 267.0% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | -12,144 | 0 | - | |
| Tax | Rs m | 6,009 | -2,994 | -200.7% | |
| Profit after tax | Rs m | 32,093 | 21,812 | 147.1% | |
| Gross profit margin | % | 21.7 | 25.9 | 83.9% | |
| Effective tax rate | % | 12.0 | -15.9 | -75.2% | |
| Net profit margin | % | 11.0 | 2.7 | 406.6% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 310,692 | 448,537 | 69.3% | |
| Current liabilities | Rs m | 173,396 | 327,033 | 53.0% | |
| Net working cap to sales | % | 47.2 | 15.1 | 312.3% | |
| Current ratio | x | 1.8 | 1.4 | 130.6% | |
| Inventory Days | Days | 99 | 84 | 118.5% | |
| Debtors Days | Days | 112 | 93 | 119.6% | |
| Net fixed assets | Rs m | 232,477 | 155,818 | 149.2% | |
| Share capital | Rs m | 2,399 | 428 | 561.0% | |
| Net worth | Rs m | 414,091 | 868,974 | 47.7% | |
| Long term debt | Rs m | 15,226 | 937,902 | 1.6% | |
| Total assets | Rs m | 646,938 | 2,330,927 | 27.8% | |
| Interest coverage | x | 10.0 | 1.5 | 675.8% | |
| Debt to equity ratio | x | 0 | 1.1 | 3.4% | |
| Sales to assets ratio | x | 0.4 | 0.3 | 130.4% | |
| Return on assets | % | 5.8 | 2.6 | 224.4% | |
| Return on equity | % | 7.8 | 2.5 | 308.8% | |
| Return on capital | % | 10.2 | 3.2 | 319.8% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 21,965 | 166,916 | 13.2% | |
| From Investments | Rs m | -6,813 | -86,277 | 7.9% | |
| From Financial Activity | Rs m | -27,305 | -77,759 | 35.1% | |
| Net Cashflow | Rs m | -8,442 | 1,383 | -610.5% | |
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.28 Rs / USD
Compare SUN PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare SUN PHARMA With: STRIDES PHARMA SCIENCE JUBILANT LIFE SCIENCES FDC LTD. NOVARTIS TORRENT PHARMA
Today's Market
Sensex Ends 226 Points Higher; Capital Goods and Banking Stocks Witness Buying(Closing)
Indian share markets ended their trading session on a positive note today. At the closing bell, the BSE Sensex stood higher by 226 points (up 0.6%).
Related Views On News
SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)
Aug 14, 2019 | Updated on Aug 14, 2019For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Aug 6, 2019 | Updated on Aug 6, 2019Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)
May 30, 2019 | Updated on May 30, 2019For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Dec 20, 2018 | Updated on Dec 20, 2018Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsMost Popular
Bet on These Smallcap Stocks for Success in 2020 (Profit Hunter)
Jan 14, 2020The smallcap rebound finally seems to here... Make sure you aren't too late to make the most of the biggest wealth making opportunity in a decade.
Guess Which Stocks Are Rising at Double the Speed of Sensex (Profit Hunter)
Jan 15, 2020These stocks can move twice as fast as the Sensex - to take advantage of their money multiplying power get in now as the rally is still just taking shape.. read more to not miss out.
For 1,000%+ Gains, Follow the 8-Year Cycle in the Stock Market (Fast Profits Daily)
Jan 17, 2020This is how the biggest trading profits are made.
What the Infosys Results Tell Us About the Next Infosys (The 5 Minute Wrapup)
Jan 15, 2020If you're interested in the next Infosys, I'll tell you where to look.
How to Buy the Best Safe Stocks in 2020 (The 5 Minute Wrapup)
Jan 17, 2020Don't fall for the safe stocks narrative going around in the stock market these days.
More